Eterna Therapeutics Inc. has entered into a sponsored research agreement with a collaborator at The University of Texas MD Anderson Cancer Center (MD Anderson).
Turnstone Biologics Corp. has received IND clearance from the FDA for the company's lead selected tumor-infiltrating lymphocyte (TIL) therapy program, TIDAL-01.
Researchers from Duality Biologics (Suzhou) Co. Ltd. presented preclinical data for a novel Trop-2-targeting antibody-drug conjugate (ADC), DB-1305, being developed for the treatment of solid tumors.
Arbutus Biopharma Corp. has described programmed cell death 1 ligand 1 (PD-L1) antagonists reported to be useful for the treatment of cancer, hepatitis B and hepatitis D viral infection.
Simcere Pharmaceutical Group announced that the FDA has cleared the company’s IND application for SIM-0237 for the treatment of adult patients with advanced solid tumors.
CSPC Pharmaceutical Group Ltd. announced that the National Medical Products Administration of the People’s Republic of China has granted approval to conduct clinical trials of the company’s antibody-drug conjugate candidate, SYS-6002.
Novaccess Global Inc. has announced the approval of its application with the FDA for orphan drug designation for TLR-AD1, a vaccine immunotherapy for the treatment of aggressive brain cancers, including glioblastoma and other high-grade gliomas. The company’s therapeutic path involves a unique transformational process, which involves the addition of proprietary substances to create a cocktail for more personalized treatment that substantially increases clinical benefits for patients.
Turn Biotechnologies Inc. has presented interim preclinical data that demonstrates treating T cells with its proprietary technologies can significantly increase their ability to kill cancer.
Bolt Biotherapeutics Inc. has presented new 2-amino-4-carboxamide-benzazepine antibody-drug conjugates (ADCs) comprising antibodies covalently linked to TLR7 and/or TLR8 agonists through a linker and reported to be useful for the treatment of cancer.
Domain Therapeutics SA has received clinical trial application (CTA) clearances in France and Belgium for its immuno-oncology program DT-9081, allowing the initiation of a phase I trial for solid tumors.
RSS
